Long‐COVID syndrome‐associated brain fog and chemofog: Luteolin to the rescue. (12th April 2021)

• Record Type: Journal Article
• Authors: Theoharides, Theoharis C.; Cholevas, Christos; Polyzoidis, Konstantinos; Politis, Antonios
• Other Names: Theoharides Theoharis guestEditor.
• Is Part Of: BioFactors. Volume 47:Number 2(2021)
• Page Start: 232
• Page End: 241
• Publication Date: 2021-04-12
• Subjects: brain fog -- chemotherapy -- coronavirus -- COVID‐19 -- cytokines -- fatigue -- inflammation -- mast cells -- microglia; Vitamins -- Physiological effect -- Periodicals; Trace elements -- Physiological effect -- Periodicals; Growth factors -- Physiological effect -- Periodicals; Plant growth promoting substances -- Physiological effect -- Periodicals; Biochemistry -- Periodicals; Nutritional Physiological Phenomena -- Periodicals; Trace Elements -- metabolism -- Periodicals; Vitamins -- metabolism -- Periodicals; Molecular Biology -- Periodicals; 612.399
• DOI: 10.1002/biof.1726
• Languages: English
• ISSNs: 0951-6433

Abstract

Abstract: COVID‐19 leads to severe respiratory problems, but also to long‐COVID syndrome associated primarily with cognitive dysfunction and fatigue. Long‐COVID syndrome symptoms, especially brain fog, are similar to those experienced by patients undertaking or following chemotherapy for cancer (chemofog or chemobrain), as well in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) or mast cell activation syndrome (MCAS). The pathogenesis of brain fog in these illnesses is presently unknown but may involve neuroinflammation via mast cells stimulated by pathogenic and stress stimuli to release mediators that activate microglia and lead to inflammation in the hypothalamus. These processes could be mitigated by phytosomal formulation (in olive pomace oil) of the natural flavonoid luteolin.